Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis

 

 Buy Article Permissions and Reprints

Abstract

Cancer-associated thrombosis (CAT) is a major cause of both morbidity and mortality in cancer patients. Platelet count has been investigated as a predictor of CAT in various settings while knowledge on platelet activation parameters is sparse. This report provides a systematic review and meta-analysis on available literature on associations between platelet count and/or function and arterial and venous thrombosis in adult cancer patients. The review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. PubMed and Embase were searched up to March 2022. The National Heart, Lung, and Blood Institute's tools were used for quality assessment. In total, 100 studies were included which investigated the association between CAT and platelet count (n = 90), platelet indices (n = 19), and platelet function/activation markers (n = 13) in patients with solid cancers (n = 61), hematological cancers (n = 17), or mixed cancer types (n = 22). Eighty-one studies had venous thrombosis as their outcome measure, while 4 had arterial thrombosis and 15 studies had both. We found significantly elevated odds ratio of 1.50 (95% confidence interval: 1.19–1.88) for thrombosis with higher platelet counts. We saw a tendency toward an association between markers of platelet activation in forms of mean platelet volume and soluble P selectin and both arterial and venous thrombosis. Only one study investigated dynamic platelet function using flow cytometry. In conclusion, platelet count is associated with CAT across different cancer types and settings. Platelet function or activation marker analysis may be valuable in assisting thrombosis risk assessment in cancer patients but is sparsely investigated so far.

Publication History

Article published online:
15 March 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Connolly GC, Francis CW. Cancer-Associated Thrombosis. American Society of Hematology Education Program; 2013: 684-691
  Google Scholar
• 2 Kim AS, Khorana AA, McCrae KR. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res 2020; 225: 33-53
  CrossrefPubMedGoogle Scholar
• 3 Navi BB, Reiner AS, Kamel H. et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70 (08) 926-938
  CrossrefPubMedGoogle Scholar
• 4 Riedl J, Pabinger I, Ay C. Platelets in cancer and thrombosis. Hamostaseologie 2014; 34 (01) 54-62
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Khorana AA, Cohen AT, Carrier M. et al. Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open 2020; 5 (06) e000948
  CrossrefPubMedGoogle Scholar
• 6 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  CrossrefPubMedGoogle Scholar
• 7 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
  CrossrefPubMedGoogle Scholar
• 8 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
  CrossrefPubMedGoogle Scholar
• 9 Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Intern Emerg Med 2012; 7 (03) 291-292
  CrossrefPubMedGoogle Scholar
• 10 Louzada ML, Carrier M, Lazo-Langner A. et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (04) 448-454
  CrossrefPubMedGoogle Scholar
• 11 van Es N, Di Nisio M, Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102 (09) 1494-1501
  CrossrefPubMedGoogle Scholar
• 12 Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, Wysokinska EM, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost 2016; 14 (09) 1773-1778
  CrossrefPubMedGoogle Scholar
• 13 Muñoz Martín AJ, García Alfonso P, Rupérez Blanco AB, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M. Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. Clin Transl Oncol 2014; 16 (10) 927-930
  CrossrefPubMedGoogle Scholar
• 14 Simanek R, Vormittag R, Ay C. et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010; 8 (01) 114-120
  CrossrefPubMedGoogle Scholar
• 15 Khorana AA, Mackman N, Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022; 8 (01) 11
  CrossrefPubMedGoogle Scholar
• 16 Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer Therapy-Associated Thrombosis. Arterioscler Thromb Vasc Biol 2021; 41 (04) 1291-1305
  CrossrefPubMedGoogle Scholar
• 17 Connolly GC, Phipps RP, Francis CW. Platelets and cancer-associated thrombosis. Semin Oncol 2014; 41 (03) 302-310
  CrossrefPubMedGoogle Scholar
• 18 Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res 2015; 135 (Suppl 1): S8-S11
  CrossrefPubMedGoogle Scholar
• 19 Cooke NM, Egan K, McFadden S. et al. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med 2013; 2 (04) 564-570
  CrossrefPubMedGoogle Scholar
• 20 Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92 (01) 185-190
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Cella G, Marchetti M, Vianello F. et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 2010; 104 (01) 151-156
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Peterson JE, Zurakowski D, Italiano Jr JE. et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012; 15 (02) 265-273
  CrossrefPubMedGoogle Scholar
• 23 Panella TJ, Peters W, White JG, Hannun YA, Greenberg CS. Platelets acquire a secretion defect after high-dose chemotherapy. Cancer 1990; 65 (08) 1711-1716
  CrossrefPubMedGoogle Scholar
• 24 The National Heart, Lung, and Blood Institute (NHLBI). Study Quality Assessment Tools. 2013. Accessed February 20, 2023 at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
  PubMed
• 25 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
  CrossrefPubMedGoogle Scholar
• 26 Afsar CU, Gunaldi M, Kum P. et al. Pancreatic carcinoma, thrombosis and mean platelet volume: single center experience from the southeast region of Turkey. Asian Pac J Cancer Prev 2014; 15 (21) 9143-9146
  CrossrefPubMedGoogle Scholar
• 27 Akkiz H, Carr BI, Yalçın K K. et al. Characteristics of hepatocellular carcinoma aggressiveness factors in Turkish patients. Oncology 2018; 94 (02) 116-124
  CrossrefPubMedGoogle Scholar
• 28 Al-Asadi O, Almusarhed M, Eldeeb H. Predictive risk factors of venous thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single Centre cohort study. Thromb J 2019; 17 (01) 2
  CrossrefPubMedGoogle Scholar
• 29 Albertin CL, Uppal S, Al-Niaimi AN, Seo S, Hinshaw JL, Hartenbach EM. Thrombocytosis is predictive of postoperative pulmonary embolism in patients with gynecologic cancer. Int J Gynecol Cancer 2015; 25 (06) 1096-1101
  CrossrefPubMedGoogle Scholar
• 30 Boone BA, Zenati MS, Rieser C. et al. Risk of venous thromboembolism for patients with pancreatic ductal adenocarcinoma undergoing preoperative chemotherapy followed by surgical resection. Ann Surg Oncol 2019; 26 (05) 1503-1511
  CrossrefPubMedGoogle Scholar
• 31 Carr BI, Guerra V. HCC and its microenvironment. Hepatogastroenterology 2013; 60 (126) 1433-1437
  PubMedGoogle Scholar
• 32 Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013; 58 (06) 1790-1796
  CrossrefPubMedGoogle Scholar
• 33 Chen L, Feng Q, Wang W, Liu L. Incidence and related factors for low-extremity deep vein thrombosis in breast cancer patients who underwent surgical resection: what do we know and what should we care. Front Surg 2022; 9: 755671
  CrossrefPubMedGoogle Scholar
• 34 Chen Y, Qin QX, Qin C. et al. Specific biomarkers of prostate cancer-associated ischemic stroke: a case-control study. Med Sci Monit 2019; 25: 5536-5542
  CrossrefPubMedGoogle Scholar
• 35 Chen Y, Wang Y, Xie S. et al. A risk of venous thromboembolism algorithm as a predictor of venous thromboembolism in patients with colorectal cancer. Clin Appl Thromb Hemost 2021; 27: 107 60296211064900
  CrossrefPubMedGoogle Scholar
• 36 Cui LN, Li N, Fu S, Zhang X, Wang X, Wang RT. Combination of preoperative D-dimer and mean platelet volume predicts postoperative deep venous thrombosis in breast cancer patients. Cancer Biomark 2018; 21 (04) 909-913
  CrossrefPubMedGoogle Scholar
• 37 Epstein AS, Soff GA, Capanu M. et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer 2012; 118 (12) 3053-3061
  CrossrefPubMedGoogle Scholar
• 38 Falvella FS, Cremolini C, Miceli R. et al. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. Pharmacogenomics J 2017; 17 (04) 331-336
  CrossrefPubMedGoogle Scholar
• 39 Ferroni P, Guadagni F, Riondino S. et al. Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica 2014; 99 (10) 1638-1644
  CrossrefPubMedGoogle Scholar
• 40 Ferroni P, Riondino S, Formica V. et al. Venous thromboembolism risk prediction in ambulatory cancer patients: clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. Int J Cancer 2015; 136 (05) 1234-1240
  CrossrefPubMedGoogle Scholar
• 41 Filippova OT, Kim SW, Cowan RA. et al. Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. Int J Gynecol Cancer 2020; 30 (08) 1183-1188
  CrossrefPubMedGoogle Scholar
• 42 Fu X, Lu P, Ye G. et al. Analysis of the risk factors of peripherally inserted central catheter-associated venous thrombosis after chemotherapy in patients with lung cancer. Int J Clin Exp Med 2019; 12 (05) 5852-5859
  PubMedGoogle Scholar
• 43 Gerotziafas GT, Taher A, Abdel-Razeq H. et al; COMPASS–CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist 2017; 22 (10) 1222-1231
  CrossrefPubMedGoogle Scholar
• 44 Grilz E, Posch F, Königsbrügge O. et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost 2018; 118 (11) 1875-1884
  Article in Thieme ConnectPubMedGoogle Scholar
• 45 Guven DC, Aksun MS, Sahin TK. et al. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. Support Care Cancer 2021; 29 (09) 5417-5423
  CrossrefPubMedGoogle Scholar
• 46 Iwata S, Kawai A, Ueda T, Ishii T. Japanese Musculoskeletal Oncology Group (JMOG). Symptomatic venous thromboembolism in patients with malignant bone and soft tissue tumors: a prospective multicenter cohort study. Ann Surg Oncol 2021; 28 (07) 3919-3927
  CrossrefPubMedGoogle Scholar
• 47 Kenmotsu H, Notsu A, Mori K. et al. Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. Cancer Med 2021; 10 (03) 895-904
  CrossrefPubMedGoogle Scholar
• 48 Kim SY, Burns ZT, Henry DH. The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy. Thromb Res 2012; 130 (06) 967-970
  CrossrefPubMedGoogle Scholar
• 49 Koksal D, Safak O, Ozcan A, Agackiran Y, Erturk H, Findik G. Thromboembolic events in malignant pleural mesothelioma. Clin Appl Thromb Hemost 2016; 22 (04) 390-394
  CrossrefPubMedGoogle Scholar
• 50 Kuk A, Magnowska M, Suchy W. et al. Retrospective evaluation of thromboembolism risk in ovarian cancer patients treated with bevacizumab. Target Oncol 2017; 12 (04) 495-503
  CrossrefPubMedGoogle Scholar
• 51 Lin BX, Xu CS. Risk factors of PICC-related venous thrombosis in breast cancer patients undergoing chemotherapy. Int J Gen Med 2021; 14: 1337-1341
  CrossrefPubMedGoogle Scholar
• 52 Li N, Zhang FB, Li BJ, Wang RT. Combination of preoperative D-dimer and platelet distribution width predicts postoperative deep venous thrombosis in patients with cervical carcinoma. Asian Pac J Cancer Prev 2019; 20 (04) 1025-1029
  CrossrefPubMedGoogle Scholar
• 53 Li Z, Zhang G, Zhang M, Mei J, Weng H, Peng Z. Development and validation of a risk score for prediction of venous thromboembolism in patients with lung cancer. Clin Appl Thromb Hemost 2020; 26: 107 6029620910793
  CrossrefPubMedGoogle Scholar
• 54 López-Salazar J, Ramírez-Tirado LA, Gómez-Contreras N. et al. Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. Intern Med J 2020; 50 (03) 366-370
  CrossrefPubMedGoogle Scholar
• 55 Ma SG, Hu J, Huang Y. The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: a meta-analysis. Thromb Res 2020; 196: 325-334
  CrossrefPubMedGoogle Scholar
• 56 Man YN, Wang YN, Hao J. et al. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism. Int J Gynecol Cancer 2015; 25 (01) 24-32
  CrossrefPubMedGoogle Scholar
• 57 Mandalà M, Barni S, Prins M. et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010; 21 (04) 871-876
  CrossrefPubMedGoogle Scholar
• 58 Matsuo K, Hasegawa K, Yoshino K. et al. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 2015; 51 (14) 1978-1988
  CrossrefPubMedGoogle Scholar
• 59 Matsuo K, Yessaian AA, Lin YG. et al. Predictive model of venous thromboembolism in endometrial cancer. Gynecol Oncol 2013; 128 (03) 544-551
  CrossrefPubMedGoogle Scholar
• 60 Merkow RP, Bilimoria KY, McCarter MD. et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg 2011; 254 (01) 131-137
  CrossrefPubMedGoogle Scholar
• 61 Monreal M, Alastrue A, Rull M. et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75 (02) 251-253
  Article in Thieme ConnectPubMedGoogle Scholar
• 62 Navi BB, Sherman CP, Genova R. et al. Mechanisms of ischemic stroke in patients with cancer: a prospective study. Ann Neurol 2021; 90 (01) 159-169
  CrossrefPubMedGoogle Scholar
• 63 Nie D, Yang E, Li Z. Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis. BMC Cancer 2019; 19 (01) 73
  CrossrefPubMedGoogle Scholar
• 64 Park H, Jeong CW, Yuk H. et al. Influence of tumor thrombus on occurrence of distant venous thromboembolism and survival in patients with renal cell carcinoma after surgery. Clin Appl Thromb Hemost 2019; 25: 107 6029618823288
  CrossrefPubMedGoogle Scholar
• 65 Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9 (09) 1826-1830
  CrossrefPubMedGoogle Scholar
• 66 Peng SY, Wei T, Li XY, Yuan Z, Lin Q. A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study. Support Care Cancer 2022; 30 (02) 1127-1137
  CrossrefPubMedGoogle Scholar
• 67 Pin S, Mateshaytis J, Ghosh S, Batuyong E, Easaw JC. Risk factors for venous thromboembolism in endometrial cancer. Curr Oncol 2020; 27 (04) 198-203
  CrossrefPubMedGoogle Scholar
• 68 Poruk KE, Firpo MA, Huerter LM. et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2010; 19 (10) 2605-2610
  CrossrefPubMedGoogle Scholar
• 69 Quan X, Qin Q, Chen Y. et al. Independent risk factors and the potential predictors of bladder cancer-related ischemic stroke. J Int Med Res 2020; 48 (04) 30 0060520919227
  CrossrefPubMedGoogle Scholar
• 70 Riedl J, Kaider A, Marosi C. et al. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. Thromb Haemost 2017; 117 (01) 90-98
  Article in Thieme ConnectPubMedGoogle Scholar
• 71 Rink M, Riethdorf S, Yu H. et al. The impact of circulating tumor cells on venous thromboembolism and cardiovascular events in bladder cancer patients treated with radical cystectomy. J Clin Med 2020; 9 (11) 3478
  CrossrefPubMedGoogle Scholar
• 72 Schlick CJR, Liu JY, Yang AD, Bentrem DJ, Bilimoria KY, Merkow RP. Pre-operative, intra-operative, and post-operative factors associated with post-discharge venous thromboembolism following colorectal cancer resection. J Gastrointest Surg 2020; 24 (01) 144-154
  CrossrefPubMedGoogle Scholar
• 73 Schorling RM, Pfrepper C, Golombek T. et al. Evaluation of biomarkers for the prediction of venous thromboembolism in ambulatory cancer patients. Oncol Res Treat 2020; 43 (09) 414-427
  CrossrefPubMedGoogle Scholar
• 74 Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost 2010; 8 (08) 1702-1709
  CrossrefPubMedGoogle Scholar
• 75 Shi S, Cheng J, Zhao Y, Chen W. Incidence, and preoperative and intraoperative prognostic factors of deep venous thrombosis in patients with glioma following craniotomy. Clin Neurol Neurosurg 2021; 210: 106998
  CrossrefPubMedGoogle Scholar
• 76 Suzuki T, Fujino S, Inaba S. et al. Venous thromboembolism in patents with lung cancer. Clin Appl Thromb Hemost 2020; 26: 107 6029620977910
  CrossrefPubMedGoogle Scholar
• 77 Thaler J, Ay C, Kaider A. et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncol 2014; 16 (12) 1645-1651
  CrossrefPubMedGoogle Scholar
• 78 Tsoukalas N, Papakotoulas P, Christopoulou A. et al. Real-world data on thromboprophylaxis in active cancer patients: Where are we? Are we getting there?. Cancers (Basel) 2020; 12 (07) 1907
  CrossrefPubMedGoogle Scholar
• 79 Uhrig M, Simons D, Schlemmer HP. Incidental pulmonary emboli in stage IV melanoma patients: prevalence in CAT staging examinations and improved detection with vessel reconstructions based on dual energy CAT. PLoS One 2018; 13 (07) e0199458
  CrossrefPubMedGoogle Scholar
• 80 von Tempelhoff GF, Niemann F, Schneider DM, Kirkpatrick CJ, Hommel G, Heilmann L. Blood rheology during chemotherapy in patients with ovarian cancer. Thromb Res 1998; 90 (02) 73-82
  CrossrefPubMedGoogle Scholar
• 81 Wu X, Xue X, Tang J. et al. Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23 (01) 65-72
  CrossrefPubMedGoogle Scholar
• 82 Xian Z, Chen Y, Chen L. et al. A clinical research on the potential pathogenesis of somatic cancer related cerebral venous sinus thrombosis. Medicine (Baltimore) 2019; 98 (19) e15134
  CrossrefPubMedGoogle Scholar
• 83 Yamagata K, Fukuzawa S, Uchida F, Ishibashi-Kanno N, Yanagawa T, Bukawa H. Is preoperative plate-lymphocyte ratio a predictor of deep vein thrombosis in patients with oral cancer during surgery?. J Oral Maxillofac Surg 2021; 79 (04) 914-924
  CrossrefPubMedGoogle Scholar
• 84 Yu I, Chen L, Ruan JY, Chang JT, Cheung WY. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. Support Care Cancer 2016; 24 (03) 1199-1208
  CrossrefPubMedGoogle Scholar
• 85 Zhang W, Liu X, Cheng H, Yang Z, Zhang G. Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China. Medicine (Baltimore) 2018; 97 (31) e11754
  CrossrefPubMedGoogle Scholar
• 86 Al-Ani F, Wang YP, Lazo-Langner A. Development of a clinical prediction rule for venous thromboembolism in patients with acute leukemia. Thromb Haemost 2020; 120 (02) 322-328
  Article in Thieme ConnectPubMedGoogle Scholar
• 87 Bagratuni T, Kastritis E, Politou M. et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am J Hematol 2013; 88 (09) 765-770
  CrossrefPubMedGoogle Scholar
• 88 Boersma RS, Hamulyak K, van Oerle R, Tuinenburg A, Ten Cate-Hoek AJ, Schouten HC. Biomarkers for prediction of central venous catheter related-thrombosis in patients with hematological malignancies. Clin Appl Thromb Hemost 2016; 22 (08) 779-784
  CrossrefPubMedGoogle Scholar
• 89 Chang H, Kuo MC, Shih LY. et al. Acute promyelocytic leukemia-associated thrombosis. Acta Haematol 2013; 130 (01) 1-6
  CrossrefPubMedGoogle Scholar
• 90 Del Principe MI, Buccisano F, Maurillo L. et al. Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. Thromb Res 2013; 132 (05) 511-514
  CrossrefPubMedGoogle Scholar
• 91 Kato A, Takano H, Ichikawa A. et al. A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res 2013; 131 (02) 140-144
  CrossrefPubMedGoogle Scholar
• 92 Kirkizlar O, Alp Kirkizlar T, Umit EG. et al. The incidence of venous thromboembolism and impact on survival in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2020; 20 (08) 542-547
  CrossrefPubMedGoogle Scholar
• 93 Libourel EJ, Klerk CPW, van Norden Y. et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood 2016; 128 (14) 1854-1861
  CrossrefPubMedGoogle Scholar
• 94 Li X, Hou SL, Li X. et al. Risk factors of thromboembolism in lymphoma patients undergoing chemotherapy and its clinical significance. Clin Appl Thromb Hemost 2021; 27: 107 60296211037923
  CrossrefPubMedGoogle Scholar
• 95 Martella F, Cerrano M, Di Cuonzo D. et al. Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. Ann Hematol 2022; 101 (04) 855-867
  CrossrefPubMedGoogle Scholar
• 96 Qian H, Liu J, Xu C, Zhu W, Chen L. Predisposing factors and effect of bundle nursing in PICC-related upper extremity deep venous thrombosis in patients with non-Hodgkin's lymphoma undergoing chemotherapy. Am J Transl Res 2021; 13 (08) 9679-9686
  PubMedGoogle Scholar
• 97 Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget 2018; 9 (30) 21190-21200
  CrossrefPubMedGoogle Scholar
• 98 Rupa-Matysek J, Gil L, Kroll-Balcerzak R, Barańska M, Komarnicki M. Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. Hematol Oncol 2017; 35 (04) 456-464
  CrossrefPubMedGoogle Scholar
• 99 Sanfilippo KM, Carson KR, Wang TF. et al. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost 2022; 6 (01) e12634
  CrossrefPubMedGoogle Scholar
• 100 Vu K, Luong NV, Hubbard J. et al. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med 2015; 4 (01) 27-35
  CrossrefPubMedGoogle Scholar
• 101 Yuen HLA, Slocombe A, Heron V. et al. Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. Res Pract Thromb Haemost 2020; 4 (06) 997-1003
  CrossrefPubMedGoogle Scholar
• 102 Zhang X, Guo X. Risk factors of thrombosis in Chinese subjects with acute promyelocytic leukemia. Thromb J 2021; 19 (01) 42
  CrossrefPubMedGoogle Scholar
• 103 Ahmed S, Shahid RK, Bhatt H, Lee-Ying R, Lim J. Chemotherapy-related thrombocytosis: does it increase the risk of thromboembolism?. Oncology 2012; 82 (06) 327-332
  CrossrefPubMedGoogle Scholar
• 104 Ashrani AA, Gullerud RE, Petterson TM, Marks RS, Bailey KR, Heit JA. Risk factors for incident venous thromboembolism in active cancer patients: a population based case-control study. Thromb Res 2016; 139: 29-37
  CrossrefPubMedGoogle Scholar
• 105 Ay C, Simanek R, Vormittag R. et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112 (07) 2703-2708
  CrossrefPubMedGoogle Scholar
• 106 Babilonia KM, Golightly LK, Gutman JA. et al. Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization. Clin Appl Thromb Hemost 2014; 20 (08) 799-806
  CrossrefPubMedGoogle Scholar
• 107 Dickmann B, Ahlbrecht J, Ay C. et al. Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica 2013; 98 (08) 1309-1314
  CrossrefPubMedGoogle Scholar
• 108 Gong J, Drobni ZD, Alvi RM. et al. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer 2021; 158: 99-110
  CrossrefPubMedGoogle Scholar
• 109 Grilz E, Marosi C, Königsbrügge O. et al. Association of complete blood count parameters, D-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. J Thromb Haemost 2019; 17 (08) 1335-1344
  CrossrefPubMedGoogle Scholar
• 110 Haire WD, Lieberman RP, Edney J. et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990; 66 (05) 900-908
  CrossrefPubMedGoogle Scholar
• 111 Kewan T, Ko T, Flores M, Sallam Y, Haddad A, Daw H. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors. Eur J Haematol 2021; 106 (05) 682-688
  CrossrefPubMedGoogle Scholar
• 112 Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12) 2822-2829
  CrossrefPubMedGoogle Scholar
• 113 Khorana AA, Kamphuisen PW, Meyer G. et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH Trial. J Clin Oncol 2017; 35 (10) 1078-1085
  CrossrefPubMedGoogle Scholar
• 114 Kitayama H, Kondo T, Sugiyama J. et al. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. BMC Cancer 2017; 17 (01) 351
  CrossrefPubMedGoogle Scholar
• 115 Moore RA, Adel N, Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
  CrossrefPubMedGoogle Scholar
• 116 Peippo MH, Kurki S, Lassila R, Carpén OM. Real-world features associated with cancer-related venous thromboembolic events. ESMO Open 2018; 3 (05) e000363
  CrossrefPubMedGoogle Scholar
• 117 Riedl J, Hell L, Kaider A. et al. Association of platelet activation markers with cancer-associated venous thromboembolism. Platelets 2016; 27 (01) 80-85
  CrossrefPubMedGoogle Scholar
• 118 Riedl J, Kaider A, Reitter EM. et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost 2014; 111 (04) 670-678
  Article in Thieme ConnectPubMedGoogle Scholar
• 119 Sinnamon AJ, Tong JKC, Bailey EA. et al. Prospective implementation of a standardized screening protocol for deep venous thrombosis in abdominal surgical oncology patients. J Surg Oncol 2018; 118 (03) 568-573
  CrossrefPubMedGoogle Scholar
• 120 Sutandyo N, Tobing DL. Kardinah. Risk factors of deep vein thrombosis in cancer patients. Iran J Blood Cancer 2018; 10 (04) 117-123
  PubMedGoogle Scholar
• 121 van Es N, Louzada M, Carrier M. et al. Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study. Thromb Res 2018; 163: 41-46
  CrossrefPubMedGoogle Scholar
• 122 Vemulapalli S, Chintala L, Tsimberidou AM. et al. Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 2009; 84 (07) 408-413
  CrossrefPubMedGoogle Scholar
• 123 Zhang X, Huang JJ, Xia Y. et al. High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. Oncotarget 2016; 7 (23) 35404-35411
  CrossrefPubMedGoogle Scholar
• 124 Agnelli G, Bolis G, Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (01) 89-95
  CrossrefPubMedGoogle Scholar
• 125 Adelborg K, Veres K, Horváth-Puhó E. et al. Thrombocytopenia among patients with hematologic malignancies and solid tumors: risk and prognosis. Blood 2021; 138 (Suppl 1): 3156-3156
  CrossrefPubMedGoogle Scholar
• 126 Skipper MT, Rubak P, Stentoft J, Hvas AM, Larsen OH. Evaluation of platelet function in thrombocytopenia. Platelets 2018; 29 (03) 270-276
  CrossrefPubMedGoogle Scholar
• 127 Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20 (04) 365-372
  CrossrefPubMedGoogle Scholar
• 128 Montoro-García S, Schindewolf M, Stanford S, Larsen OH, Thiele T. The role of platelets in venous thromboembolism. Semin Thromb Hemost 2016; 42 (03) 242-251
  Article in Thieme ConnectPubMedGoogle Scholar
• 129 Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-Associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018; 10 (10) 380
  CrossrefPubMedGoogle Scholar
• 130 Bath P, Algert C, Chapman N, Neal B. PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35 (03) 622-626
  CrossrefPubMedGoogle Scholar
• 131 Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø Study, Tromsø, Norway. J Thromb Haemost 2010; 8 (01) 157-162
  CrossrefPubMedGoogle Scholar
• 132 Chu SG, Becker RC, Berger PB. et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8 (01) 148-156
  CrossrefPubMedGoogle Scholar
• 133 Cil H, Yavuz C, Islamoglu Y. et al. Platelet count and mean platelet volume in patients with in-hospital deep venous thrombosis. Clin Appl Thromb Hemost 2012; 18 (06) 650-653
  CrossrefPubMedGoogle Scholar
• 134 Slavka G, Perkmann T, Haslacher H. et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol 2011; 31 (05) 1215-1218
  CrossrefPubMedGoogle Scholar
• 135 Mutlu H, Artis TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost 2013; 19 (03) 331-333
  CrossrefPubMedGoogle Scholar
• 136 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103 (04) 491-495
  CrossrefPubMedGoogle Scholar
• 137 Tscharre M, Vogel B, Tentzeris I. et al. Prognostic impact of soluble P-selectin on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention. Thromb Haemost 2019; 119 (02) 340-347
  Article in Thieme ConnectPubMedGoogle Scholar
• 138 Ay C, Jungbauer LV, Sailer T. et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 2007; 53 (07) 1235-1243
  CrossrefPubMedGoogle Scholar
• 139 Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost 2013; 11 (02) 223-233
  CrossrefPubMedGoogle Scholar
• 140 Mi Y, Yan S, Lu Y, Liang Y, Li C. Venous thromboembolism has the same risk factors as atherosclerosis: a PRISMA-compliant systemic review and meta-analysis. Medicine (Baltimore) 2016; 95 (32) e4495
  CrossrefPubMedGoogle Scholar
• 141 Prisco D, D'Elios MM, Cenci C, Ciucciarelli L, Tamburini C. Cardiovascular oncology: a new discipline inside internal medicine?. Intern Emerg Med 2014; 9 (04) 359-364
  CrossrefPubMedGoogle Scholar

• Supplementary Material